Andere talen Otsuka Holdings Co., Ltd.

Aandelen

4578

JP3188220002

Farmaceutische producten

Beurs gesloten - Japan Exchange Andere beurzen 07:30:00 12-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9.312,00 ^JPY	+0,13%		+1,65%	+8,28%

26/11	Otsuka ontvangt versnelde goedkeuring van de Amerikaanse FDA voor VOYXACT	MT
26/11	Otsuka Holdings ontvangt versnelde FDA-goedkeuring voor VOYXACT bij behandeling van IgA-nefropathie	RE

Andere talen

Bourse : Thales et Dassault vont créer une IA de guerre, Dell séduit au contraire de HP	26/11
Le marché retrouve son Mojo	26/11
Otsuka Wins U.S. FDA Accelerated Approval for VOYXACT	26/11
Otsuka Holdings Co receives FDA accelerated approval for Voyxact for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression	26/11
Fda approves use of Voyxact to reduce proteinuria in primary immunoglobulin	25/11
US FDA approves Otsuka's drug for a type of kidney disease	25/11
Ema's CHMP announces positive recommendation on extension of therapeutic indications for Koselugo	14/11
Japanese Shares Rise as U.S. Shutdown Deal Nears	10/11
Otsuka Pharmaceutical, Co. Ltd. Announces Findings from 12-Month Interim Analysis of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults	10/11
Otsuka's Sibeprenlimab Shows 54% Reduction in Proteinuria in Phase 3 IgAN Trial	10/11
4D Molecular Shares Rise Premarket on Partnership With Otsuka	31/10
Otsuka Holdings Nine-Month Profit Rises 55%	31/10
Otsuka Holdings Co., Ltd. Reaffirms Consolidated Financial Forecast for the Fiscal Year Ending December 31, 2025	31/10
Nikkei ends at three-week low on profit-taking as second half of fiscal year begins	01/10
Nikkei falls on profit-taking at start of second half of fiscal year	01/10
Japan's Topix posts record-high close despite US tariffs on pharma	26/09
Japan's Topix hits record high despite US tariffs on pharma	26/09
Otsuka Completes Transfer of MicroPort Stake Held By Medical Devices Unit	22/09
Otsuka Pharmaceutical Co., Ltd. Receives Complete Response Letter from U.S. FDA for sNDA of REXULTI (Brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder	22/09
US FDA Rejects Otsuka and Lundbeck's PTSD Drug Application	22/09
Otsuka and Lundbeck receive complete response letter from U.S. FDA for sNDA of Rexulti (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD	20/09
Otsuka and Lundbeck Receives Complete Response Letter from U.S. FDA for sNDA of REXULTI®? (Brexpiprazole) in Combination with Sertraline for the Treatment of Adults with PTSD	20/09
Otsuka Profit Increases 27% in H1	01/08
Otsuka Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	31/07
Otsuka Holdings Co., Ltd. Declares Dividend for the Second Quarter Ended June 30, 2025, Payable on September 1, 2025 and Revises Dividend Guidance for the Fiscal Year Ending December 31, 2025	31/07

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Otsuka Holdings Co., Ltd.

Aandelen

4578

JP3188220002

Farmaceutische producten

Andere talen

Filters